Pneumothorax following combination chemotherapy with bevacizumab: A case report and review of the literature

Alrifai, Taha; Saba, Raya; Rifai, Dana; Pandit, Sarbagya; Kozma, Kelley Elizabeth

doi:10.3892/mco.2019.1868

Cited by 6 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case, the treatment for pneumothorax took approximately 1 month. However, there are also reports of other malignancies, including breast cancer, that require treatment for 2 months or more [ 8 ]. In advanced cases, bevacizumab in combination with chemotherapy is often introduced in the treatment of breast cancer, as it has been shown to have a high rate of tumor shrinkage and prolongation of progression-free survival [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

A Case of Pneumothorax Required Surgical Treatment as a Complication of Paclitaxel with Bevacizumab Treatment

Moriya,

Oshino,

Hosoda

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

A 63-year-old woman had a history of neoadjuvant chemotherapy, mastectomy, and adjuvant endocrine therapy for 5 years before being diagnosed with recurrent lesions involving the right anterior chest wall, multiple lymph nodes, and pulmonary metastases. The patient was subsequently initiated on a paclitaxel and bevacizumab regimen. During this treatment, the patient complained of palpitations and malaise. Chest radiography revealed a left pneumothorax. Despite attempts at conservative treatment, the pneumothorax did not improve and a thoracoscopic approach was required. One of the metastatic tumors in the left lower lobe appeared to rupture, and this area was estimated to be the cause of air leak. The tumor was covered with a tissue seal sheet, and the patient’s condition improved with no recurrence of pneumothorax. This case highlights the importance of early conversion to surgical treatment when conservative treatment for pneumothorax is unresponsive due to the potential side effects of bevacizumab. The findings of this case report may be of interest to oncologists, pulmonologists, and other healthcare professionals involved in the care of patients with breast cancer and pulmonary metastases who are undergoing bevacizumab chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A Case of Pneumothorax Required Surgical Treatment as a Complication of Paclitaxel with Bevacizumab Treatment

Moriya,

Oshino,

Hosoda

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

“…The usual time frame, as reported in other case reports, is consistent with this case, wherein it occurred after four cycles of chemotherapy. Many chemotherapeutic agents (actinomycin-D, bevacizumab, bleomycin, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, erlotinib, etoposide, gefitinib, gemcitabine, paclitaxel, pemetrexed, oxaliplatin, vinblastine, vinorelbine) [ 19 , 20 ] have been implicated in causing pneumothorax. In our case, both doxorubicin and cyclophosphamide were used, and both drugs were incriminated as potential causative agents for pneumothorax.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy Associated Bilateral Secondary Spontaneous Pneumothorax

Singh¹,

Dua²,

Baishya³

et al. 2022

Cureus

View full text Add to dashboard Cite

Chemotherapy-associated pneumothorax is a rarely encountered oncological emergency. Herein, we present a rare chemotherapy-associated bilateral secondary spontaneous pneumothorax case of a man in his 60s with invasive breast carcinoma after four cycles of chemotherapy. He presented to our emergency department with acute onset dyspnea and left-sided pleuritic chest pain. A chest X-ray showed a left-sided pneumothorax, and an intercostal chest tube (ICT) was inserted with underwater seal drainage. After three days, he complained of sudden onset right-sided chest pain and increased dyspnea. A repeat chest X-ray revealed right-sided pneumothorax, which was managed with ICT again. Bilateral pleurodesis was done after a repeat chest x-ray showed complete lung re-expansion. The patient was doing well with no recurrence of pneumothorax after three months of follow-up. Male breast cancer is uncommon, and presentation with bilateral secondary spontaneous pneumothorax is rare. This case is reported as a rare complication of chemotherapy-associated bilateral spontaneous pneumothorax.

show abstract

“…As shown in Table 4 , the shared targets of apatinib and pazopanib include vascular endothelial growth factor receptors (VEGFRs) and stem cell factor receptor (KIT). We performed a literature search and found that bevacizumab and ramucirumab, single-target inhibitors of the VEGFR signaling pathway, can cause pneumothorax [ 21 – 23 ]. However, imatinib, which targets KIT but not VEGFRs (Table 4 ) [ 24 ], has not been reported to cause pneumothorax.…”

Section: Discussionmentioning

confidence: 99%

Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis

Tian

Liu

Zhao³

et al. 2020

Anti-Cancer Drugs

View full text Add to dashboard Cite

This study was performed to investigate pneumothorax characteristics and association with clinical outcomes in patients with osteosarcoma treated with apatinib. We retrospectively reviewed the medical records of osteosarcoma patients treated with apatinib between January 2016 and April 2020 at three institutions. We evaluated the prevalence, healing time, recurrence, severity, clinical management, and prognosis of pneumothorax in these patients. A total of 54 osteosarcoma patients who received apatinib treatment were enrolled in this study. Among them, 14 patients had pneumothorax. There were significant differences between the patients with and without pneumothorax with regard to the cavitating rate of lung metastases (92.86 vs. 32.50%, respectively, P < 0.001), objective response rate (42.86 vs. 10.00%, P = 0.013), disease control rate (85.71 vs. 42.50%, P = 0.006), 4-month progression-free survival (PFS) rate (57.10 vs. 20.00%, P < 0.001), and median PFS (5.65 vs. 2.90 months, P = 0.011). Compared with pneumothorax patients treated with chest tube drainage only [non-staphylococcal enterotoxin C (SEC) group], those treated with chest tube drainage and SEC thoracic perfusion in parallel (SEC group) had a shorter pneumothorax healing time (12.00 ± 4.50 days vs. 24.00 ± 14.63 days for SEC group and non-SEC group, respectively, P = 0.103), a lower recurrence rate of pneumothorax (25.00% vs. 66.67%, P = 0.277), and a longer median PFS (5.9 months vs. 4.75 months, P = 0.964). however, these numerical differences for the SEC/non-SEC data did not reach statistical significance. Pneumothorax and cavitation in lung metastases may be effective prognostic markers for patients with osteosarcoma treated with apatinib. SEC may be effective for treatment of such pneumothorax patients, warranting further study.

show abstract

Pneumothorax following combination chemotherapy with bevacizumab: A case report and review of the literature

Cited by 6 publications

References 19 publications

A Case of Pneumothorax Required Surgical Treatment as a Complication of Paclitaxel with Bevacizumab Treatment

A Case of Pneumothorax Required Surgical Treatment as a Complication of Paclitaxel with Bevacizumab Treatment

Chemotherapy Associated Bilateral Secondary Spontaneous Pneumothorax

Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis

Contact Info

Product

Resources

About